Stock Taper 
Standard BioTools Inc. develops and sells proteomics and genomics instruments, consumables, and services globally, including platforms like SomaScan and CyTOF, for biomedical research and therapeutic development.
The Hyperion XTi Imaging System uses Imaging Mass Cytometry to analyze over 40 biomarkers simultaneously on tissue samples, offering high-speed, automated, multiplexed imaging for deep spatial insights in oncology and immunology research.
Standard BioTools announced preliminary fourth quarter and full-year 2025 revenue that surpassed the company's previous guidance. The company highlighted steady execution and progress on its path to profitability, which was met with a significant positive market reaction.
Standard BioTools executed a strategic divestiture of its SomaLogic proteomics business to Illumina. This move significantly alters the company's financial and operational landscape, providing a substantial capital infusion intended to fuel a new strategy focused on inorganic growth through acquisitions.
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 CGEM | $15.49 | COMPARE |
 CBLL | $23.18 | COMPARE |
 BVS | $12.67 | COMPARE |
 VREX | $18.46 | COMPARE |
 CTKB | $5.32 | COMPARE |
 KIDS | $21.87 | COMPARE |
 SY | $2.46 | COMPARE |
 TMCI | $3.88 | COMPARE |
